Zacks.com on MSN20h
Biotech Stock Roundup: BBIO Stock Up on Drug Approval, SAVA, APLT Plunge on Setbacks & MorePipeline and regulatory updates are in focus in the biotech sector. Among these, BridgeBio Pharma, Inc. BBIO gained on ...
Stocktwits on MSN4d
BridgeBio Stock Hits 2-Month Highs After Analysts Cheer FDA Nod For Heart Drug: Retail Excitement BuildsBridgeBio Pharma Inc. ($BBIO) stock surged 28% on Monday morning, hitting highs last seen in mid-September, after the company ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin (TTR) for adults with ATTR-CM ...
We recently compiled a list of the 10 Worst Performing Biotech Stocks in 2024. In this article, we are going to take a look ...
Oppenheimer analyst Trevor Allred maintained a Hold rating on BridgeBio Pharma (BBIO – Research Report) today. The company’s shares opened ...
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
On Friday, BridgeBio Pharma Inc (BBIO) stock saw a modest uptick, ending the day at $23.42 which represents a slight increase of $0.18 or 0.77% from the prior close of $23.24. The stock opened at $23.
(BBIO), the company announced that its innovative drug, Attruby (acoramidis), has received FDA approval for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). This approval, granted by ...
On Monday, BridgeBio Pharma, Inc. (NASDAQ:BBIO) presented initial outcomes from the ATTRibute-CM open-label extension (OLE) ...
In a report released today, Cory Kasimov from Evercore ISI reiterated a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback